Skip to main content

Table 2 Summary of patient characteristics, clinical indicators, and patient outcomes

From: The use of monoclonal antibody therapy in pediatric patients with COVID-19: a retrospective case series

  N = 44 n (%)
Monoclonal antibody therapy  
 Bamlanivimab 24 (56)
 Bamlanivimab/etesevimab 10 (23)
 Casirivmab/imdevimab 10 (23)
Age (years)  
median (interquartile range) 15 (14–16)
 12 to 13 9 (21)
 14 to 15 17 (39)
 16 to 17 18 (42)
Gender  
 Female 25 (57)
 Male 19 (43)
Race  
 Caucasian 23 (52)
 Hispanic 11 (25)
 Black 10 (23)
Days of symptoms before MCA  
Median (interquartile range) 4 (2-7)
 0 to 3 18 (41)
 4 to 5 11 (25)
 6 to 9 15 (34)
Risk factors (patient may have more ≥ 1 factor)  
 Obesity 35 (80)
 Asthma 19 (43)
 Developmental delay 2 (4.5)
 Hypertension 1 (2.3)
 Chest pain 1 (2.3)
 Congenital heart disease 1 (2.3)
 Insulin dependent diabetes mellitus 1 (2.3)
Body mass index  
> 85th percentile 35 (80)
Steroid use  
 Last 7 days 6 (14)
Initial oxygen saturation (%)  
Median (interquartile range) 98 (98–99)
 Normal, ≥ 95 42 (95)
 Abnormal, < 95 2 (4.5)
Initial heart rate (bpm)  
Median (interquartile range) 89 (79–104)
 Normal, < 120 41 (93)
 Abnormal, > 120 3 (6.8)
Initial respiratory rate (breaths per minute)  
Median (interquartile range) 20 (18–20)
 Normal, < 24 41 (93)
 Abnormal, ≥ 24 3 (6.8)
Body temperature (celsius)  
Median (interquartile range) 36.9° (36.7°–37.4°)
 Normal, < 38 °C 43 (98)
 Abnormal, ≥ 38 °C 1 (2.3)
Clinical outcomes  
 Infusion-related event 1 (2.3)
 ED visit within 28 days 2 (4.7)
 Hospitalization within 28 days 0 (0)
  1. MCA monoclonal antibody, bpm breaths per minute, ED emergency department